Contact

History

JPT Peptide Technologies GmbH is a leading provider of innovative peptide-based services, and catalog products & kits, as well as a research and development partner for projects in Immunology, Proteomics and Drug Discovery.
JPT's head office and production sites are located in Berlin, Germany. All of its production and services are performed in Berlin/ Germany in accordance with DIN EN ISO 9001:2015 guidelines.
Together with its US-subsidiary based in Acton, near Boston, Massachusetts, JPT is serving a worldwide customer base in the pharmaceutical and biotechnology industries, as well as researchers in universities, governmental and non-profit organizations. Over the past decade, JPT has developed a portfolio of proprietary technologies and a series of unique products and services which support research efforts in proteomics, all development phases of novel vaccines or immunotherapies and peptides based drug discovery.

history
2004 JPT Peptide Technologies GmbH was established as a spin-off of Jerini AG, a Berlin based peptide drug discovery company.
DIN ISO 9001:2000 Certification
2008 JPT became a wholly owned subsidiary of BioNTech AG, Mainz (Germany), a company that develops novel immune therapy and diagnostic approaches for various cancers. GCLP Compliance Audits (NIH, IAVI, BCM, Cellmedica, Genticel, Karolinska)
2009 JPT is actively involved in R&D partnerships and contract research projects focusing on seromarker discovery & validation, development of immune monitoring tools and diagnostics, vaccine target discovery, peptide lead identification & optimization, biomarker quantification by targeted proteomics, enzyme substrate identification & sensitivity profiling.
2010 DIN ISO 9001:2008 Certification
2011 JPT launched an online shop to ease the access to its unique portfolio of catalog peptide microarrays, peptide pools and intelligent peptide collections.
2012 JPT's HIV microarrays and cyclic peptides used for analysis of HIV Vaccine Trial RV144 (Karasavvas et al., AIDS Res Hum Retroviruses, 2012)
2013 JPT conducts first its hands-on workshop: Microarray Application Training.
2014 JPT's peptide technologies are successfully used in various clinical immunotherapy developments.
JPT's scientists and technologies helped to decipher the Human Proteome (Wilhelm et al., Nature, 2014).
We celebrate our 10th anniversary.
2015 JPT completes its product and service portfolio for all developments phases of immunotherapies and vaccines ranging from deep target and epitope discovery to clinical applications.
JPT starts work to create the largest repository of peptides consisting of > 1 Mio peptides for MS-based proteomics (ProteomeTools project).
2016 DIN ISO 9001:2015 Certification
2017 JPT expands its peptide capacities for applications in cellular therapy and clinical immune monitoring.

 

 

Stay in touch and be the first to receive the latest news!